Status:
TERMINATED
Antidepressant Response in Older Adults With Comorbid PTSD and MDD
Lead Sponsor:
New York State Psychiatric Institute
Conditions:
Post Traumatic Stress Disorder
Major Depressive Disorder
Eligibility:
All Genders
60-105 years
Phase:
PHASE4
Brief Summary
In the Investigator's ongoing studies of Posttraumatic Stress Disorder (PTSD) in older adults, it has been found that older adults with PTSD frequently meet the criteria for comorbid Major Depressive ...
Detailed Description
Chronic PTSD in older adults leads to increased risk of mortality from cardiovascular disease, metabolic syndrome, diabetes mellitus, and ulcerative gastrointestinal disease. PTSD appears to promote a...
Eligibility Criteria
Inclusion
- Individual has completed IRB 7489
- Diagnosed with DSM 5 MDD
- HRSD \>=18
- Willing to and capable of providing informed consent and complying with study procedures.
Exclusion
- History of allergic or adverse reaction to
- Non-response to adequate trial of escitalopram (at least 4 weeks at dose of 20mg) and duloxetine (at least 4 weeks at dose of 60mg)during the current episode.
- Current treatment with psychotherapy, antidepressants, or other psychotropic medications.
Key Trial Info
Start Date :
March 3 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 20 2021
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT04697693
Start Date
March 3 2021
End Date
May 20 2021
Last Update
May 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York State Psychiatric Institute
New York, New York, United States, 10032